Blueprint Medicines Corp reports results for the quarter ended in December - Earnings Summary

Blueprint Medicines

15/02/2024 14:31

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $1.82​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-2.65.  The mean expectation of
eighteen analysts for the quarter was for a loss of $2.04 per
share. Wall Street expected results to range from $-2.28
to $-1.80 per share.
    * Revenue rose 85.5% to $71.96 million from a year ago;
analysts
expected $66.28 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $1.82​.
    * The company reported a quarterly loss of $110.92 million.
    * Blueprint Medicines Corp shares had fallen by 16.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Blueprint
Medicines Corp is $94.00 
This summary was machine generated from LSEG data February 15 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -2.04          -1.82          Beat
 Sep. 30 2023      -2.37          -2.20          Beat
 Jun. 30 2023      -2.54          -2.19          Beat
 Mar. 31 2023      -2.67          -2.15          Beat